Cryoport, Inc. filings document the regulatory record for a Nasdaq-listed Nevada corporation providing temperature-controlled supply chain solutions to life sciences customers. Recent Form 8-K reports furnish quarterly and annual results releases, while definitive proxy materials describe governance matters, stockholder voting items and business updates tied to Life Sciences Services and Life Sciences Products.
The filing record also identifies Cryoport's registered common stock and recurring disclosure subjects such as operating performance, commercial and clinical cell and gene therapy support, biostorage and bioservices activity, cryogenic systems demand, executive and board governance, and stockholder meeting materials.
Cryoport, Inc. disclosed a planned sale of up to 28,800 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an aggregate value of $426,816.00 as of 08/11/2026. The shares come from restricted stock units and previously exercised holdings acquired on 02/29/2012.
Cryoport, Inc. reported Q2 2026 total revenue of $48,971 (thousands), up from $45,454 (thousands) a year earlier, driven by Life Sciences Services of $27,969 (thousands) and Life Sciences Products of $21,002 (thousands). Gross margin was $22,824 (thousands), while loss from operations was $(10,039) (thousands).
Loss from continuing operations was $(8,255) (thousands), or $(0.20) per share, compared with $(12,014) (thousands), or $(0.28) per share, in Q2 2025. For the first six months of 2026, revenue reached $96,769 (thousands) and net loss was $(18,799) (thousands). Cash and cash equivalents were $269,267 (thousands) and short-term investments $127,426 (thousands), for total liquidity of $396,693 (thousands), versus Convertible Senior Notes principal of $186,185 (thousands) due in 2026. Prior-year results included a $120,883 (thousands) gain from the June 2025 sale of the CRYOPDP business, classified as discontinued operations.
Cryoport, Inc. reported Q2 2026 revenue of $48,971 thousand, up 8% year-over-year, and first-half revenue of $96,769 thousand, up 12%. Life Sciences Services grew 15% to $27,969 thousand, driven by 13% growth in BioLogistics Solutions and 25% growth in BioStorage/BioServices, while Life Sciences Products was flat at $21,002 thousand.
Cell and gene therapy activity remained strong, with $9.4 million in commercial CGT revenue, $13.4 million from supporting CGT clinical trials, and a record 779 supported trials worldwide, including 94 in Phase 3. GAAP loss from continuing operations narrowed to $8,255 thousand from $12,014 thousand a year earlier, and adjusted EBITDA from continuing operations turned positive at $375 thousand versus a prior loss of $914 thousand.
As of June 30, 2026, Cryoport held $269,267 thousand in cash and cash equivalents and $127,426 thousand in short-term investments, against total liabilities of $265,505 thousand and stockholders’ equity of $490,699 thousand, including a current portion of convertible senior notes of $185,687 thousand.
Cryoport, Inc. has a Schedule 13G/A filed by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander regarding holdings of Cryoport common stock. Integrated Core Strategies reports 1,556,718 shares with shared voting and dispositive power, representing 3.1% of the common stock. Millennium Management, Millennium Group Management and Mr. Englander each report shared voting and dispositive power over 1,724,726 shares, representing 3.4% of the class. The filers state that they beneficially own 5 percent or less of the outstanding common stock.
Cryoport, Inc.’s Chief Digital and Tech Officer, Edward J. Zecchini, reported a paired option exercise and share sale over two days. He exercised stock options covering 35,000 shares of common stock at an exercise price of $4.80 per share and sold 35,000 shares of common stock in open-market transactions.
The sales occurred at weighted average prices of about $15.23 on June 10, 2026 and $14.47 on June 11, 2026, with trades executed in narrow price ranges as disclosed. Following these transactions, he directly holds 109,719 shares of Cryoport common stock, and the option position referenced in this filing has been fully exercised.
Regulation 144 notice: A proposed sale of 33,600 shares of common stock scheduled 06/11/2026 arising from the exercise of options under a registered plan, executed through Morgan Stanley Smith Barney LLC. The filing also reports an actual sale of 1,400 shares by Edward Zecchini on 06/10/2026 for $21,323.96.
Cryoport, Inc. reported results from its 2026 Annual Meeting of Stockholders. Shareholders elected six directors, with votes for each nominee ranging from 38.9 million to 40.9 million, with additional broker non-votes recorded.
Stockholders ratified Deloitte & Touche LLP as independent auditor with 47,014,962 votes for. They approved executive compensation on an advisory basis with 39,533,693 votes for, and approved an amendment to the 2018 Omnibus Equity Incentive Plan to increase authorized shares, with 30,110,893 votes for and 12,591,758 against.
Cryoport, Inc. director Linda Baddour received new equity compensation on June 5, 2026. She was granted 10,350 restricted stock rights that vest in full on June 5, 2027 and will convert into 10,350 shares of common stock on a one-for-one basis at that time.
She also received options to buy 16,077 shares of common stock at an exercise price of $15.70 per share. One-twelfth of these options vest on the 5th of each month for twelve months beginning July 5, 2026, and they expire on June 5, 2033. Following the restricted stock grant, she directly holds 68,099 common shares.